🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain Tumors
Organization UNIVERSITY OF TEXAS HLTH SCIENCE CENTERLocation SAN ANTONIO, UNITED STATESPosted 8 Mar 2021Deadline 28 Feb 2026 ⚠️
NIHUS FederalResearch GrantFY20250-11 years oldAddressAstrocytic GliomaAstrocytic NeoplasmAstrocytic TumorAstrocytomaAstrogliomaB-raf-1BRAFBRAF geneBourneville DiseaseBourneville PhakomatosisBourneville syndromeBourneville-Brissaud diseaseBourneville-Pringle syndromeBrain NeoplasiaBrain NeoplasmsBrain TumorsCNS TumorCNS neoplasmCancersCause of DeathCell Communication and SignalingCell DeathCell SignalingCentral Nervous System NeoplasmsCentral Nervous System TumorsChildChild YouthChildhoodChildhood Brain NeoplasmChildhood Brain TumorChildhood CNS NeoplasmChildhood CNS TumorChildhood Central Nervous System NeoplasmChildhood Central Nervous System TumorChildhood GlioblastomaChildhood GliomaChildhood NeoplasmChildhood Pilocytic AstrocytomaChildhood TumorChildren (0-21)Children's Oncology GroupClinicalClinical TrialsCombined Modality TherapyComplexCytotoxic agentCytotoxic drugDNA DamageDNA InjuryDNA mutationDataData BasesDatabasesDiffuse astrocytomaDiseaseDisease ProgressionDisorderDoseDrug CombinationsDrug TherapyDrug resistanceDrugsEpiloiaGangliogliomaGenetic ChangeGenetic defectGenetic mutationGlial Cell TumorsGlial NeoplasmGlial TumorGlioblastomaGliomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaIntracellular Communication and SignalingInvestigatorsJuvenile Pilocytic AstrocytomasLaboratoriesLow Dose RadiationLytotoxicityMAP Kinase Kinase 1MAP kinaseMAP2K1MAP2K1 geneMAPK InhibitorsMAPK Signaling PathwayMAPK Signaling Pathway PathwayMAPK/ERK Kinase 1MAPKK1MEK-1MEK1MEKsMKK1Malignant NeoplasmsMalignant TumorMediatingMedicationMitogen-Activated Protein Kinase InhibitorMitogen-Activated Protein Kinase Kinase-1Mitogen-Activated Protein KinasesModelingMultimodal TherapyMultimodal TreatmentMutationNF-1NF-1 ProteinNF-1 encoded proteinNF1NF1 GRPNF1 ProteinNF1 geneNF1-GAP-Related ProteinNeurofibromatosis 1 GenesNeurofibromatosis Type 1 Gene ProductNeurofibromatosis Type 1 ProteinNeurofibrominNeurofibromin 1Neuroglial NeoplasmNeuroglial TumorOutcomePDX modelPRKMK1Pathway interactionsPatient derived xenograftPatientsPediatric Brain Tumor ConsortiumPediatric GlioblastomaPediatric Glioblastoma multiformePediatric GliomaPediatric NeoplasmPediatric Oncology GroupPediatric Pilocytic AstrocytomaPediatric TumorPediatric high-grade gliomaPharmaceutical PreparationsPharmacological TreatmentPharmacologyPharmacotherapyPhasePhase 1/2 trialPhase I/II TrialPhosphorylationPoint MutationPreclinical dataPringle diseaseProtein PhosphorylationQOLQuality of lifeRAFB1Radiation PhysicsRadiation therapyRadioresistanceRadiotherapeuticsRadiotherapyRapamuneRapamycinRegimenRelapseReportingResearchResearch PersonnelResearchersResistanceResistance developmentResistant developmentSignal PathwaySignal TransductionSignal Transduction SystemsSignalingSirolimusTSC2TSC2 geneTSC4TSC4 GeneTestingTherapeuticToxic effectToxicitiesTranslatingTranslational ResearchTranslational ScienceTuberinTuberous SclerosisTumor Celladenoma sebaceumbiological signal transductioncancer progressioncell killingcerebral sclerosischemo-/radio-therapychemo-radiotherapychemoradiationchemoradiation therapychemoradiation treatmentchemoradiotherapychild patientscombination therapycombined modality treatmentcombined treatmentcytotoxicitydata basedevelop drug resistancedeveloping resistancedriver lesiondriver mutationdrug interventiondrug resistance developmentdrug resistantdrug treatmentdrug/agentepiploiagenome mutationglial-derived tumorglioblastoma multiformehereditary multiple system hamartomatosisimprovedinhibitorinhibitor druginhibitor therapeuticinhibitor therapykidsmalignancymouse modelmulti-modal therapymulti-modal treatmentmultidisciplinarymurine modelmutantnecrocytosisneoplasm progressionneoplasm/cancerneoplastic cellneoplastic progressionneurinomatosis centralisneurofibromatosis type 1 geneneurofibromatosis type 1 protein/geneneuroglia neoplasmneuroglia tumorneuromatosis universalisneurospongioblastosis diffusanext generationnf 1 Genesnovelpathwaypatient derived xenograft modelpediatricpediatric CNS neoplasmpediatric CNS tumorpediatric brain neoplasmpediatric brain tumorpediatric central nervous system neoplasmpediatric central nervous system tumorpediatric low grade gliomapediatric patientsphacomatosispharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticsphase 2 trialphase II trialpre-clinicalpre-clinical studypreclinicalpreclinical findingspreclinical informationpreclinical studypreventpreventingradiation resistanceradiation treatmentradio resistanceradio-chemo-therapyradio-chemotherapyradiochemotherapyresistance mechanismresistance to Drugresistantresistant mechanismresistant to Drugresponsesclerosis tuberosaspongioblastoma multiformespongioblastosis circumscriptatargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttranslation researchtranslational investigationtreatment with radiationtuberose sclerosistuberous sclerosis complextumortumor diagnosistumor of the central nervous systemtumor progressiontumors in childrentumors in the braintumors in the central nervous systemv-raf Murine Sarcoma Viral Oncogene Homolog B1youngster
Applications closed.
Description preview
Pediatric glioma is characterized by activation of the MAPK pathway, either through a tandem duplication of
the BRAFA locus, or through point mutations (most frequently the V600E mutation). Approximately 1400 new
cases of BRAF-activated childhood brain tumors are diagnosed annually in the US. Recent phase I/II trials have
confirmed the efficacy of…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click